GLIOMATCH is a Horizon Europe project dedicated to pioneering targeted treatments for brain cancer. Led by KU Leuven, the project brings together more than a dozen partners from ten EU member states to advance personalised medicine for one of the most lethal cancer types. In line with Europe’s Beating Cancer Plan, GLIOMATCH contributes to the EU Cancer Mission’s objectives through the ‘Understanding (Tumour-Host) Interactions’ Cluster. By making technology for customised treatments accessible to clinicians, GLIOMATCH aims to relieve the burden brain tumours place on patients, families, and healthcare systems across Europe.
Find out more about the GLIOMATCH project by watching our explainer video. In the video, Prof. Frederik De Smet (KUL), GLIOMATCH project coordinator, breaks down the project’s objectives, innovation, and overall structure.
In this GLIOMATCH: Explained episode, Dr. Chiara Caprioli and Prof. Frederik De Smet from KU Leuven explain how new research has mapped the evolution of glioblastoma from diagnosis to recurrence, identified distinct tumour trajectories and established a framework that could support more personalised treatment decisions.
In this GLIOMATCH: Explained episode, Prof. Dr. Sandra Jacobs introduces the paediatric clinical study, the participating centres and the challenges of working with archived samples from paediatric high-grade glioma patients.
On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.
